Doravirine vs Rilpivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Doravirine · Pifeltro
Marketed by Merck & Co.
NCT02275780 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)
Result source: NCT02403674
Rilpivirine · Edurant
Marketed by Johnson & Johnson
NCT00540449 · Phase 3 · completed
This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.
Next expected readout: December 2028 · NCT07637877 (registry estimate)
Reported efficacy
Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)
Result source: NCT00540449
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Doravirine | Rilpivirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757803 other results
| 94% vs 94%vs CARNCT0242279712 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778 | 0.6% vs 0%vs FTC/RPV/TDFNCT023452523 other results
|
| CD4 count, change (week 48) | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578014 other results
| 28 vs 18.4vs CARNCT0242279714 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Doravirine
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
3 other results
- 84.3% vs 80.8% NCT02403674
- 73.1% vs 66% NCT02275780
- 77.5% vs 73.6% NCT02403674
- Rilpivirine
- 94% vs 94%vs CARNCT02422797
12 other results
- 95% vs 96% NCT02429791
- 93.7% vs 93.9% NCT02345252
- 90% vs 92% NCT02345226
- 85.8% vs 81.6% NCT01309243
- 93.7% vs 89.9% NCT01252940
- 97% vs 98% NCT02422797
- 89.2% vs 88.5% NCT02345252
- 85.2% vs 85.1% NCT02345226
- 77.9% vs 72.4% NCT01309243
- 93.9% vs 96.2% NCT01709084
- 89.3% vs 92.1% NCT01252940
- 98% vs 96% NCT02429791
HIV-1 RNA 50 copies/mL or more (week 48)
- Doravirine
- 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778
- Rilpivirine
- 0.6% vs 0%vs FTC/RPV/TDFNCT02345252
3 other results
- 1.1% vs 0.9% NCT02345226
- 0.6% vs 1% NCT02345252
- 0.7% vs 0.9% NCT02345226
CD4 count, change (week 48)
- Doravirine
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
14 other results
- 192.7 vs 185.6 NCT02275780
- 217.1 vs 319.9 NCT04233879
- 182.4 vs 233.5 NCT04233879
- 5.4 vs 62.7 NCT04223791
- -19.7 vs 40.5 NCT04223791
- 0.5 vs 66.3 NCT04223791
- 239.6 vs 350.9 NCT04233879
- 259.2 vs 263.6 NCT01632345
- 191.9 vs 194.5 NCT01632345
- 133.6 vs 121.1 NCT01632345
- 152.3 vs 146 NCT01632345
- 140.7 vs 121.1 NCT01632345
- 112.9 vs 121.1 NCT01632345
- 154.1 vs 121.1 NCT01632345
- Rilpivirine
- 28 vs 18.4vs CARNCT02422797
14 other results
- 42 vs 42.4 NCT02422797
- 12 vs 16 NCT02345252
- 12 vs 6 NCT02345226
- 278 vs 259 NCT01309243
- 32.3 vs 41.8 NCT02429791
- 9 vs -1 NCT02345252
- 23 vs 12 NCT02345226
- 10 vs -7 NCT01252940
- 200 vs 191 NCT01309243
- 16.2 vs 47.4 NCT02429791
- 20 vs 32 NCT01252940
- 145.9 vs 159.8 NCT00110305
- 158.9 vs 159.8 NCT00110305
- 172 vs 159.8 NCT00110305
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Doravirine: 8 of 8 rows · Rilpivirine: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Doravirine Rows use multiple source trials | Rilpivirine Rows use multiple source trials |
|---|---|---|
| CD4 percent change · % of baseline No placebo or comparator arm | -0.4% (n=43) @ 48wka,b,c NCT03332095 · Phase 1/2 · combination | 6.4% (n=1) @ 48wkd,a,b,c NCT04012931 · Phase 2 · registry result, not featured evidence show 1 more dose0.7% (n=25) @ 48wk NCT04012931 · Phase 2 · registry result, not featured evidence |
| CD4+ absolute change · cells/uL No placebo or comparator arm | 42.5 cells/uL @ 96wke,b,c NCT03332095 · Phase 1/2 · combination | 72.63 cells/uL @ 96wkd,e,b,c NCT01266902 · Phase 3 · registry result, not featured evidence show 3 more doses69.76 cells/uL @ 96wk NCT01266902 · Phase 3 · registry result, not featured evidence 55.91 cells/uL @ 96wk NCT01266902 · Phase 3 · registry result, not featured evidence 42.19 cells/uL @ 96wk NCT01266902 · Phase 3 · registry result, not featured evidence |
| Hip BMD percent change · % of baseline Maintenance | 0.6% (n=35) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mgd,f,g,c NCT04636437 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-0.81% (n=40) vs -0.17% (n=39) INSTI+TAF/FTC @ 48wk100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination | 1.279% (n=347) vs -0.134% (n=367) EFV/FTC/TDF @ 48wkf,g,c NCT02345226 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 92.5% (n=40) @ 96wke,b,h NCT03332095 · Phase 1/2 · combination | 85% (n=252) @ 148wke,b,h NCT02429791 · Phase 3 · registry result, not featured evidence · combination 1 other source trial84% (n=261) @ 148wkDTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 24.2%100 mgi NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 19.6%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 10%Cohort 1: DOR NCT03332095 · Phase 1/2 2.2%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 20.4%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 8.2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 0% NCT04689737 · Phase 4 · registry result, not featured evidence 30.4%DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 80.2%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 17%Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 42.9%DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 33.3%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 43.6%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 28.6% NCT04900974 · Phase 1 · registry result, not featured evidence 0% NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 24.3%j NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results20% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 5.2%DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 6.1%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01709084 · Phase 3 · registry result, not featured evidence 22.3%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 25.2%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence 12.7%FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 15.7%FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 8.1% NCT01252940 · Phase 3 · registry result, not featured evidence 21% NCT01309243 · Phase 3 · registry result, not featured evidence 0% NCT04012931 · Phase 2 · registry result, not featured evidence 30.6%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 40%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 33.3%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence 12.1% NCT02165202 · Phase 2 · registry result, not featured evidence 4% NCT01286740 · Phase 2 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence 7.1% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1.6%100 mgi NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 3%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 —Cohort 1: DOR NCT03332095 · Phase 1/2 —Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination — NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence — NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination —200 mg NCT01466985 · Phase 1 · registry result, not featured evidence —25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 3.5%j NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results5.3% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 2.4%DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 4.2%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01709084 · Phase 3 · registry result, not featured evidence 3%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 2.5%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence 0.6%FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 1.1%FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence —Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 0.9% NCT01252940 · Phase 3 · registry result, not featured evidence 3% NCT01309243 · Phase 3 · registry result, not featured evidence — NCT04012931 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —25 mg NCT00799864 · Phase 2 · registry result, not featured evidence —15 mg NCT00799864 · Phase 2 · registry result, not featured evidence —12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence — NCT02165202 · Phase 2 · registry result, not featured evidence — NCT01286740 · Phase 2 · registry result, not featured evidence —50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence — NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 11.7%100 mgi NCT02275780 · Phase 3 · combination show 44 more results6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 6%DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 4.5%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 5.2%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 6.3%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 8.2%DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 —MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 0%Cohort 1: DOR NCT03332095 · Phase 1/2 4.4%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 10.6%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 25% NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 4.3%DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 6.2%DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.6%DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.5%DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 6.4%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 5.3%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.1%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 0%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.7%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.8%Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence 4%Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence 3.7%Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 2.7%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 10.2%100 mg NCT01632345 · Phase 2 · registry result, not featured evidence 7.3%200 mg NCT01632345 · Phase 2 · registry result, not featured evidence 2.3%50 mg NCT01632345 · Phase 2 · registry result, not featured evidence 10%25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 0% NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 11.6%j NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 32 more results9.4% NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 —DTG + RPV NCT02429791 · Phase 3 · registry result, not featured evidence · combination 3.2%DTG + RPV (Continuation Phase) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 13.5%DTG + RPV (Early + Late Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination 4%DTG + RPV (Early Switch) NCT02429791 · Phase 3 · registry result, not featured evidence · combination —DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 5.8%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 14.6%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.3%DTG 50 mg + RPV 25 mg NCT02422797 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01709084 · Phase 3 · registry result, not featured evidence 4.4%RPV (TMC278-TiDP6-C209 [C209] and NCT01266902 · Phase 3 · registry result, not featured evidence 7.6%Rilpivirine (RPV) (TMC278-C204 [C2 NCT01266902 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF NCT02345252 · Phase 3 · registry result, not featured evidence 11.4%FTC/RPV/TAF (Double-Blind Phase) NCT02345252 · Phase 3 · registry result, not featured evidence 5.3%Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence 0%Open-Label FTC/RPV/TAF From FTC/RP NCT02345252 · Phase 3 · registry result, not featured evidence —FTC/RPV/TAF NCT02345226 · Phase 3 · registry result, not featured evidence 12.3%FTC/RPV/TAF (Double-Blind Phase) NCT02345226 · Phase 3 · registry result, not featured evidence 4.8%Open-Label FTC/RPV/TAF From EFV/FT NCT02345226 · Phase 3 · registry result, not featured evidence 0%Open-Label FTC/RPV/TAF From FTC/RP NCT02345226 · Phase 3 · registry result, not featured evidence 6.6% NCT01252940 · Phase 3 · registry result, not featured evidence 9.1% NCT01309243 · Phase 3 · registry result, not featured evidence 0% NCT04012931 · Phase 2 · registry result, not featured evidence 16.7%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%15 mg NCT00799864 · Phase 2 · registry result, not featured evidence 0%12.5 mg NCT00799864 · Phase 2 · registry result, not featured evidence 4.4% NCT02165202 · Phase 2 · registry result, not featured evidence 2% NCT01286740 · Phase 2 · registry result, not featured evidence 0%50mg/25mg NCT03984838 · Phase 1 · registry result, not featured evidence 0% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 100 mgi diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · combination show 33 more resultsnasopharyngitis 13.7% upper respiratory tract infection 7.2% headache 6.2% NCT02403674 · Phase 3 · HIV · phase 3 nasopharyngitis 9.7% upper respiratory tract infection 7.1% diarrhoea 6.3% NCT02403674 · Phase 3 · HIV · phase 3 aspartate aminotransferase increased 22.2% blood alkaline phosphatase increased 11.1% blood glucose increased 11.1% NCT03332095 · Phase 1/2 glomerular filtration rate decreased 55.6% alanine aminotransferase increased 46.7% blood creatinine increased 46.7% NCT03332095 · Phase 1/2 · combination 100 mg creatinine renal clearance decreased 10.6% low density lipoprotein increased 6.4% abdominal pain upper 2.1% NCT04636437 · Phase 4 · registry result, not featured evidence · combination 100 mg creatinine renal clearance decreased 8.2% aspartate aminotransferase increased 4.1% alanine aminotransferase increased 2% NCT04636437 · Phase 4 · registry result, not featured evidence · combination headache 8.1% covid-19 5.9% arthralgia 5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 13.1% lymphocyte count decreased 10.5% cd4 lymphocytes decreased 9.2% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 32.3% cd4 lymphocytes decreased 23.7% covid-19 12.4% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 15.9% cd4 lymphocytes decreased 11.4% covid-19 1.5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 2.6% nasopharyngitis 2% diarrhoea 1% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 100 mg/0.75 mg covid-19 14.1% headache 10.4% lymphocyte count decreased 9.1% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 24.1% cd4 lymphocytes decreased 10.5% covid-19 7.5% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 17.1% cd4 lymphocytes decreased 8.2% upper respiratory tract infection 2.7% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 14.3% accidental overdose 0% arthralgia 0% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg upper respiratory tract infection 6.3% insomnia 1.8% headache 0.9% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 headache 10.7% accidental overdose 7.1% covid-19 5.4% NCT04223778 · Phase 3 · registry result, not featured evidence lymphocyte count decreased 20.2% cd4 lymphocytes decreased 14% covid-19 13% NCT04223778 · Phase 3 · registry result, not featured evidence covid-19 17.5% lymphocyte count decreased 13.5% cd4 lymphocytes decreased 12% NCT04223778 · Phase 3 · registry result, not featured evidence blood creatine phosphokinase increased 28.6% (placebo 14.3%) diarrhoea 28.6% (placebo 14.3%) anaemia 14.3% (placebo 0%) NCT04233216 · Phase 3 · registry result, not featured evidence · combination dizziness 33.3% dyspepsia 33.3% headache 33.3% NCT04295772 · Phase 2 · registry result, not featured evidence covid-19 100% adjustment disorder 0% back pain 0% NCT04295772 · Phase 2 · registry result, not featured evidence oropharyngeal pain 10.8% cough 8.1% nasal congestion 8.1% NCT04295772 · Phase 2 · registry result, not featured evidence cough 28.6% oropharyngeal pain 21.4% rhinorrhoea 21.4% NCT04295772 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 17.6% diarrhea 14.8% dizziness 14.8% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 29.3% nausea 22% headache 17.1% NCT01632345 · Phase 2 · registry result, not featured evidence 50 mg abnormal dreams 20.9% nausea 16.3% headache 14% NCT01632345 · Phase 2 · registry result, not featured evidence 25 mg diarrhea 25% fatigue 17.5% influenza 15% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 33.3%) abdominal pain 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence 25 mg alanine aminotransferase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 0%) decreased appetite 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence | j upper respiratory tract infection 15.3% diarrhoea 14.7% headache 14.5% NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 show 28 more resultsarthralgia 0% back pain 0% bronchitis 0% NCT02429791 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 20.6% headache 14.7% diarrhoea 13.9% NCT02429791 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% headache 9.5% diarrhoea 8.7% NCT02429791 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg arthralgia 0% asthenia 0% back pain 0% NCT02422797 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg nasopharyngitis 18.4% upper respiratory tract infection 14.2% bronchitis 10.7% NCT02422797 · Phase 3 · registry result, not featured evidence · combination DTG 50 mg + RPV 25 mg nasopharyngitis 8% upper respiratory tract infection 7.3% arthralgia 6.5% NCT02422797 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 29.6% headache 17.8% urinary tract infection 13.6% NCT01709084 · Phase 3 · registry result, not featured evidence pregnancy 1.9% headache 1.1% alanine aminotransferase increased 0.8% NCT01266902 · Phase 3 · registry result, not featured evidence facial wasting 1.7% hepatitis c 1.7% hypertension 1.7% NCT01266902 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% upper respiratory tract infection 14.9% diarrhoea 10.8% NCT02345252 · Phase 3 · registry result, not featured evidence back pain 10.5% conjunctivitis allergic 10.5% cough 10.5% NCT02345252 · Phase 3 · registry result, not featured evidence cough 17.6% nasopharyngitis 17.6% pyrexia 17.6% NCT02345252 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 16.9% nasopharyngitis 11.6% cough 10.3% NCT02345226 · Phase 3 · registry result, not featured evidence rhinitis 16% nasopharyngitis 12% bronchitis 8% NCT02345226 · Phase 3 · registry result, not featured evidence nasopharyngitis 11% diarrhoea 10.7% headache 9.8% NCT01252940 · Phase 3 · registry result, not featured evidence diarrhoea 17.5% nausea 16.5% upper respiratory tract infection 14.5% NCT01309243 · Phase 3 · registry result, not featured evidence vomiting 15.4% alanine aminotransferase increased 11.5% abdominal pain 7.7% NCT04012931 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 55.6% influenza 41.7% cough 27.8% NCT00799864 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 60% toothache 40% alanine aminotransferase increased 20% NCT00799864 · Phase 2 · registry result, not featured evidence 25 mg upper respiratory tract infection 55.6% decreased appetite 22.2% diarrhoea 22.2% NCT00799864 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 100% anaemia 50% dermatitis atopic 50% NCT00799864 · Phase 2 · registry result, not featured evidence 12.5 mg upper respiratory tract infection 100% cough 50% lower respiratory tract infection 50% NCT00799864 · Phase 2 · registry result, not featured evidence injection site pain 75% (placebo 40.5%) injection site pruritus 36.3% (placebo 11.9%) injection site swelling 36.3% (placebo 7.1%) NCT02165202 · Phase 2 · registry result, not featured evidence diarrhoea 16.3% upper respiratory tract infection 14.3% insomnia 12.2% NCT01286740 · Phase 2 · registry result, not featured evidence 50mg/25mg headache 6.3% vessel puncture site bruise 6.3% vomiting 6.3% NCT03984838 · Phase 1 · registry result, not featured evidence insomnia 23.1% NCT01562886 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 2 versus Phase 1/2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTrial phases differ: Phase 3 versus Phase 1/2.
- fTrial phases differ: Phase 3 versus Phase 4.
- gPopulation context differs: registered conditions differ.
- hAssessment timepoints differ: 148 weeks versus 96 weeks.
- iPopulation comparability has not been reviewed for 24 of these studies.
- jPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Doravirine
show 3 more results
show 3 more results
+ 36 further endpoints in the CSV export.
Rilpivirine
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Rilpivirine's landscape